Safety Alerts Saves Lives
Safety Alerts  
Home Privacy About Us Contact Us Change Preferences

December 13, 2000

Clarification Addendum: Wyeth-Ayerst Recall of Premarin® and Premphase®

Unedited Company Addendum

On October 16, 2000, Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE:AHP), voluntarily recalled 50 specific lots of Premarin® (conjugated estrogens tablets, USP) and one lot of Premphase® (conjugated estrogens/ medroxyprogesterone acetate tablets), distributed in the United States. In routine quality assurance testing, Wyeth-Ayerst identified lots that did not meet current USP dissolution specifications.

The recall is limited to specific lots of Premarin® 0.625 mg, 0.9 mg, 1.25 mg, and 2.5 mg and Premphase that are currently at wholesalers. It does not affect Premarin or Premphase in retail pharmacy outlets or product that women may have in their possession.

Women who take Premarin or Premphase from these specified lots receive the appropriate prescribed estrogen dose. These products are effective for the treatment of moderate to severe menopausal symptoms such as hot flashes, night sweats, and vaginal dryness, and for the prevention of osteoporosis.

As always, if women have questions, they should contact their health care provider, or they can call Wyeth-Ayerst Medical Affairs at 1-800-934-5556 from 8:30 a.m. to 4:30 p.m. ET.

As a leader in women’s health care, Wyeth-Ayerst takes its responsibility to women very seriously and is dedicated to providing the highest quality products.

Products in the Premarin® family have been used safely and effectively for nearly 60 years by millions of women to help relieve the symptoms of menopause, and to prevent osteoporosis.

End Addendum


The information contained herein has been obtained from sources that the Company believes to be reliable, however, the Company has not independently verified or confirmed the information and the recipient acknowledges that no representations or warranties are being made in connection with the use of the information.